Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Short term Debt (2024 - 2025)

Editas Medicine (EDIT) has disclosed Short term Debt for 2 consecutive years, with $5.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Short term Debt changed N/A to $5.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.0 million, a N/A change, with the full-year FY2024 number at $5.0 million, changed N/A from a year prior.
  • Short term Debt was $5.0 million for Q3 2025 at Editas Medicine, roughly flat from $5.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $5.0 million in Q4 2024 to a low of $5.0 million in Q4 2024.